Thromb Haemost 1989; 62(02): 686-689
DOI: 10.1055/s-0038-1646883
Original Article
Schattauer GmbH Stuttgart

DDAVP Induces Systemic Release of Urokinase-Type Plasminogen Activator

Marcel Levi
1   The Centre for Thrombosis, Hemostasis and Atherosclerosis Research, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
,
Jan W ten Cate
1   The Centre for Thrombosis, Hemostasis and Atherosclerosis Research, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
,
Gerard Dooijewaard
2   The Gaubius Institute TNO, Leiden, The Netherlands
,
Augueste Sturk
1   The Centre for Thrombosis, Hemostasis and Atherosclerosis Research, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
,
Emile J P Brommer
2   The Gaubius Institute TNO, Leiden, The Netherlands
,
Giancarlo Agnelli
3   The Istituto di Semeiotica Medica, Università di Perugia, Perugia, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 11. November 1988

Accepted after revision 05. April 1989

Publikationsdatum:
30. Juni 2018 (online)

Zoom Image

Summary

The desamino-d-arginine vasopressin (DDAVP) induced enhancement of endogenous fibrinolysis is generally attributed to the release of tissue-type plasminogen activator (t-PA) from the vessel wall.

The observation of concurrent release of urokinase-type plasminogen activator (u-PA), which eventually might cooperate in the enhanced fibrinolytic activity, has not been reported thusfar.

In a preliminary study in two healthy human volunteers we found a 1.8-fold increase of urokinase-antigen (UK-antigen) and a 1.7-fold increase of plasmin-activatable pro-urokinase (pro-UK) activity to DDAVP intravenously. The plasma-peak levels coincided with the maximal t-PA level. These responses following infusion of DDAVP were subsequently confirmed in a randomized double blind cross-over study in six human volunteers. We conclude that u-PA is released by DDAVP concurrently with t-PA and that it is presumably from the same origin as t-PA i.e. endothelial cells. u-PA and t-PA may therefore cooperate in the enhanced fibrinolytic activity upon DDAVP infusion.